Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland

Digestive Diseases and Sciences

Volumn 48, Issue 3, 2003, Pages 431-441

  Halldórsdóttir, Anna Margrét ^a   Sigurdardóttir, Margrét ^a   Jónasson, Jón Gunnlaugur ^a,b   Oddsdóttir, Margrét ^a,b   Magnússon, Jónas ^a,b   Lee, Jeffrey R ^c   Goldenring, James R ^c,d  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antralization; Dysplasia; Gastric adenocarcinoma; Metaplasia; Pseudopyloric metaplasia; Spasmolytic peptide expression; Trefoil proteins

Indexed keywords

POLYPEPTIDE; SPASMOLYTIC POLYPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GASTRECTOMY; GASTRITIS; HUMAN; ICELAND; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MALE; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPASMOLYTIC POLYPEPTIDE EXPRESSING METAPLASIA; STOMACH ADENOCARCINOMA; STOMACH BIOPSY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ICELAND; IMMUNOHISTOCHEMISTRY; MALE; METAPLASIA; MIDDLE AGED; PEPTIDES; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS;

EID: 0037341652     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022564027468     Document Type: Article

References (29)

1. Forman D, Sitas F, Newell DG, Stacey AR, Boreham J, Peto R, Campbell TC, Li J, Chen J: Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer 46:608-611, 1990
2. Fox JG, Correa P, Taylor NS, Zavala D, Fontham E, Janney F, Rodriguez E, Hunter F, Diavolitsis S: Campylobacter pylori-associated gastritis and immune response in a population at increased risk of gastric carcinoma. Am J Gastroenterol 84:775-781, 1989
3. Jaskiewicz K, Louwrens HD, Woodroof CW, Van Wyk MJ, Price SK: The association of Campylobacter pylori with mucosal pathological changes in a population at risk for gastric cancer. S Afr Med J 75:417-419, 1989
4. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK: Helicobacter pylori infection and the risk of gastric cancer. N Engl J Med 325:1127-1131, 1991
5. Forman D, Newell DG, Fullerton F, Yarnell JWG, Stacey AR, Wald N, Sitas P: Association between infection with Helicobacter pylori and risk of gastric cancer. Evidence from a prospective investigation. Br J Med 302:1302-1305, 1991
6. Nomura A, Stemmerman GN, Chyou PH, Kato I, Perez GI, Blaser MJ: Helicobacter priori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325:1132-1136, 1991
7. Peura DA: The report of the Digestive Health Initiative international update conference on Helicobacter pylori. Gastroenterology 113:S4-S8, 1997
8. Sipponen P, Marshall BJ: Gastritis and gastric cancer. Western countries. Gastroenterol Clin North Am 29:579-592, 2000
9. Correa P: A human model of gastric carcinogenesis. Cancer Res 48:3554-3560, 1988
10. Smith VC, Genta RM: Role of Helicobacter pylori gastritis in gastric atrophy, intestinal metaplasia and gastric neoplasia. Microsc Res Tech 48:313-320, 2000
11. Haggit RC: Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Patrol 25:982-993, 1994
12. Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis: The updated Sydney system. Am J Surg Pathol 20:1161-1181, 1996
13. Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T: Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 57:324-329, 1994
14. Kuipers EJ. Exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther 13:3-11, 1999
15. Schmidt PH, Lee JR, Joshi V, Playford RJ, Poulsom R, Wright NA, Goldenring JR: Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 79:639-646, 1999
16. Yamaguchi H, Goldenring JR, Kaminishi, M, Lee JR: Identification of spasmolytic polypeptide expressing metaplasia (SPEM) in remnant gastric cancer and surveillance postgastrectomy biopsies. Dig Dis Sci 47:573-578, 2002
17. 2 show altered apoptosis and differentiation with Helicobacter felis infection. Gastroenterology 114:675-689, 1998
18. Goldenring JR, Ray GS, Coffey RJ, Meunier PC, Haley PJ, Barnes B, Car BD: Reversible drug-induced oxyntic atrophy in rats. Gastroenterology 118:1080-1093, 2000
19. Taupin T, Pederson J, Familari M, Cook G, Yeomans N, Giraud A: Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium. Lab Invest 81:397-408, 2001
20. Wang TH, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox JG: Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 118:36-47, 2000
21. Yamaguchi H, Goldenring JR, Kaminishi M, Lee JR: Association of spasmolytic polypeptide expressing metaplasia (SPEM) with carcinogen administration and oxyntic atrophy in rats. Lab Invest 82:1045-1052, 2002
22. Ribieras S, Lefebvre O, Tomasetto C, Rio MC: Mouse trefoil factor genes: genomic organization, sequences and methylation analysis. Gene 266:67-75, 2001
23. Azarschab P, Al-Azzeeh E, Kornberger W, Gott P: Aspirin promotes TFF2 gene activation in human gastric cancer cell lines. FEBS Lett 488:206-210, 2001
24. Lefebcre O, Chenard MP, Masson R, Linares J, Dierich, LeMeur M, Wendling C, Tomasetto C, Chambon P, Rio MC: Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 274:259-262, 1996
25. Park WS, Oh, RR, Park JY, Lee JH, Shin MS, Kim HS, Lee HK, Kim YS, Kim SY, Lee SH, Yoo NJ, Lee JY: Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology 119:691-698, 2000
26. Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao CM, Podolsky DK, Wang TC: TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest 109:193-204, 2002
27. Wright NA, Pike C, Elia G: Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature 343:82-85, 1990
28. Whitehead R: Gastrointestinal and Oesophageal Pathology. Edinburgh, Churchill Livingstone 1989, 411 pp
29. Wong W-M, Garcia SB, Poulsom R, Goldenring JR, Wright NA: Aberrant spasmolytic polypeptide (TFF2)-expressing cell lineage (SPEM), pseudopyloric metaplasia (PPM) and the response to gastric mucosal damage. Gastroenterology 116:A525, 1999